Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 5/20 | 0.62 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.62 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.62 |
| ▸ | LTA4H | P09960 | 12/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114639 | 0.98 | PSMB1 (0.65) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL188519 | 0.98 | PSMB1 (0.65) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| Hydrochloric Acid SCHEMBL7819689 | 0.98 | PSMB1 (0.60) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL3165031 | 0.91 | HRH3 (0.67) | HRH3KDM4E | |
| SCHEMBL3144386 | 0.90 | HRH3 (0.71) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL2180987 | 0.89 | HRH3 (0.70) | HRH3 | |
| SCHEMBL183199 | 0.86 | LTA4H (0.59) | LTA4HHRH3KDM4E | |
| SCHEMBL182574 | 0.85 | HRH3 (0.69) | PSMB1PSMB5PSMB2LTA4HHRH3 | |
| SCHEMBL182770 | 0.84 | ALDH1A1 (0.57) | LTA4HKDM4E | |
| SCHEMBL20029 | 0.84 | NPC1 (0.61) | LTA4HHRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-2344494-A1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2011-07-20 | — | — | EP | claimed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | claimed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | claimed |
| EP-1289985-B1 | BETA-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE | ORTHO MCNEIL PHARM INC (US) | 2003-12-10 | — | — | EP | claimed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | claimed |
| US-20030166641-A1 | Beta-carboline derivatives useful as inhibitors of phosphodiesterase | SUI ZHIHUA (US) | 2003-09-04 | — | — | US | claimed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| EP-1289985-A2 | BETA-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-12 | — | — | EP | claimed |
| US-6492358-B2 | FOR TREATMENT OF SEXUAL DISORDERS, MALE ERECTILE DYSFUNCTION | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-10 | — | — | US | claimed |
| US-20020010189-A1 | beta-carboline derivatives useful as inhibitors of phosphodiesterase | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | claimed |
| WO-2001087038-A2 | β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-22 | — | — | WO | claimed |
| US-3978055-A | SEDATIVE, ANTIINFLAMMATORY, VASODILATION, BRONCHODILATION | DELALANDE S.A. (FR) | 1976-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | PSMB1 3882/4885PSMB5 3995/4885PSMB2 3302/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | PSMB1 4621/4885PSMB5 4361/4885PSMB2 4434/4885 |
| US-20020010189-A1 | beta-carboline derivatives useful as inhibitors of phosphodiesterase | PDE3B, PDE5A, PDE3A | PSMB1 1537/4885PSMB5 1021/4885PSMB2 2036/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | PSMB1 4621/4885PSMB5 4361/4885PSMB2 4434/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | PSMB1 1278/4885PSMB5 833/4885PSMB2 1340/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | PSMB1 4455/4885PSMB5 4005/4885PSMB2 4235/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | PSMB1 4455/4885PSMB5 4005/4885PSMB2 4235/4885 |
| US-20030166641-A1 | Beta-carboline derivatives useful as inhibitors of phosphodiesterase | PDE3B, PDE5A, PDE3A | PSMB1 1537/4885PSMB5 1021/4885PSMB2 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.